Posted by Michael Wonder on 03 Mar 2022
Antengene announces Xpovio regulatory approval in Singapore for the treatment of relapsed and/or refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma in three indications
1 March 2022 - First and only in a unique class of XPO1 inhibitors to be approved in Singapore.
Antengene announced today that Xpovio (selinexor) has been granted approval from the Health Sciences Authority in Singapore for three indications.
